BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

The Beacon trial enrolled 31 patients, randomizing them at a rate of 3:2:2 to receive a daily 45-mg oral dose of brepocitinib ...

Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing ...

Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the ...

Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more. That opens the door for smaller ...

Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their ...

Editor’s Note: This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc (NYSE:PFE) introduced the PfizerForAll digital platform in ...